Complete 2-Year Results Confirm Bayesian Analysis of the SURTAVI Trial.

Van Mieghem, Nicolas M; Popma, Jeffrey J; Deeb, G Michael; Yakubov, Steven J; Serruys, Patrick W; Windecker, Stephan; Søndergaard, Lars; Mumtaz, Mubashir; Gada, Hemal; Chetcuti, Stanley; Kleiman, Neal S; Kodali, Susheel; George, Isaac; Teefy, Patrick; Kiaii, Bob; Oh, Jae K; Kappetein, Arie Pieter; Chang, Yanping; Mugglin, Andrew S and Reardon, Michael J (2020). Complete 2-Year Results Confirm Bayesian Analysis of the SURTAVI Trial. JACC. Cardiovascular Interventions, 13(3), pp. 323-331. Elsevier 10.1016/j.jcin.2019.10.043

Text Complete 2-Year Results Conform Bayesian Analysis of the SURTAVI Trial.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (633kB)

OBJECTIVES

The aim of this study was to report the 2-year results of the SURTAVI (Surgical Replacement and Transcatheter Aortic Valve Implantation) trial and confirm the interim Bayesian analysis.

BACKGROUND

Transcatheter aortic valve replacement (TAVR) with a self-expanding valve was noninferior to surgery in patients with severe aortic stenosis and intermediate operative risk using Bayesian statistical methods. Novel Bayesian designs have been used to shorten the time to primary endpoint analysis in randomized clinical trials, although the predictive value of Bayesian analysis compared with frequentist approaches remains debated.

METHODS

The SURTAVI trial randomized 1,660 patients. An interim analysis was performed 1 year after the 1,400th patient was treated to estimate the primary 2-year endpoint of all-cause mortality or disabling strokes for all patients.

RESULTS

The Kaplan-Meier rate for the complete 2-year primary endpoint was 12.7% in the TAVR group and 12.6% in the surgery group (0.0% difference; 95% confidence interval: -3.4% to 3.5%), compared with 12.6% with TAVR and 14.0% with surgery (-1.4% difference; Bayesian credible interval: -5.2% to 2.3%) in the interim Bayesian analysis. A comparison of individual clinical, hemodynamic, and quality-of-life endpoints using Bayesian and frequentist methods found no significant differences.

CONCLUSIONS

The complete analysis of all patients with aortic stenosis at intermediate risk for surgery in the SURTAVI trial confirmed the noninferiority, with respect to the frequency of all-cause mortality or disabling stroke, of TAVR to surgery, as determined in the interim Bayesian analysis. Follow-up will extend out to 10 years.

Interest & Impact

Downloads

1 since deposited on 04 Nov 2020
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item